SCHEMBL4410550

SCHEMBL4410550

CCOC(=O)c1nc2nc(-c3ccc(F)cc3)c(-c3ccncc3)c(-c3ccc(F)cc3)c2n1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.49
MAPK14 Q16539 11/20 0.46
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 4/20 0.43
GABRA2 P47869 1/20 0.43
GABRB2 P47870 1/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GCGR P47871 1/20 0.42
CDC7 O00311 2/20 0.41
DBF4 Q9UBU7 2/20 0.41
GAA P10253 1/20 0.41
ALOX15 P16050 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4408977 0.85 MAPK14 (0.45) ALOX5MAPK14MAPK13MAPK12MAPK11
SCHEMBL4410497 0.85 MAPK14 (0.44) ALOX5MAPK14MAPK13MAPK12MAPK11
SCHEMBL4411060 0.77 MAPK14 (0.44) MAPK14ALDH1A1NPC1RAB9AMAPK13
SCHEMBL4408770 0.77 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK11
SCHEMBL1385933 0.74 MAPK14 (0.49) ALOX5MAPK14KDM4EALDH1A1HPGD
SCHEMBL4415373 0.73 MAPK14 (0.44) MAPK14GCGRMAPK13MAPK12MAPK11
SCHEMBL1386186 0.73 MAPK14 (0.55) ALOX5MAPK14KDM4EALDH1A1HPGD
SCHEMBL30944261 0.71 MAPK14 (0.64) ALOX5MAPK14KDM4EALDH1A1HPGD
SCHEMBL4409114 0.70 HTR3A (0.47) ALOX5MAPK14KDM4EALDH1A1GCGR
SCHEMBL1384340 0.70 MAPK14 (0.56) ALOX5MAPK14KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US claimed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US claimed
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US disclosed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 ALOX5 4412/4885MAPK14 36/4885KDM4E 1486/4885
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 ALOX5 4412/4885MAPK14 36/4885KDM4E 1486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.